<DOC>
	<DOCNO>NCT02857270</DOCNO>
	<brief_summary>The purpose study determine safety extracellular signal regulate kinase ( ERK1/2 ) inhibitor LY3214996 administer alone combination agent participant advance cancer .</brief_summary>
	<brief_title>A Study LY3214996 Administered Alone Combination With Other Agents Participants With Advanced/Metastatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>Have advance metastatic cancer ( solid tumor ) appropriate candidate experimental therapy . Part B2 : Have advanced/metastatic cancer carry activate mitogenactivated protein kinase ( MAPK ) pathway alteration Part B3 : Have metastatic melanoma carry BRAF mutation , refractory/relapsed treatment Raf and/or MEK inhibitor Part B4 : Have metastatic melanoma carry NRAS mutation Part C : Have advance unresectable cancer ( dose escalation ) advanced/unresectable/metastatic NSCLC carry BRAF RAS mutation colorectal cancer carry RAS mutation ( dose expansion ) Part D : Have metastatic pancreatic ductal adenocarcinoma ( dose escalation dose expansion ) Have discontinue previous treatment cancer resolution , except otherwise state inclusion criterion , clinically significant toxic effect prior chemotherapy , surgery , radiotherapy Grade ≤1 National Cancer Institute ( NCI ) Common Terminology Criteria Adverse Events ( CTCAE ) , Version 4.0 . Have adequate organ function . Have performance status 0 1 Eastern Cooperative Oncology Group ( ECOG ) scale . Have serious preexist medical condition . Have know human immunodeficiency virus ( HIV ) infection know activated/reactivated hepatitis A , B , C. Have symptomatic central nervous system malignancy metastasis . Have current hematologic malignancy , acute chronic leukemia . Have second primary malignancy judgment investigator Lilly may affect interpretation result . Have prior malignancy . Participants carcinoma situ origin participant prior malignancy remission whose likelihood recurrence low , judge Lilly clinical research physician , eligible study . Have mean QT interval correct heart rate ( QTc ) ≥470 millisecond screen electrocardiogram ( ECG ) calculate use Bazett 's formula several consecutive day assessment . Have participate , within last 28 day clinical trial involve investigational product currently enrol clinical trial involve investigational product type medical research judge scientifically medically compatible study . Have previously complete withdrawn study study investigate ERK1/2 inhibitor . If female , pregnant , breastfeeding , plan become pregnant . Have history finding central branch retinal artery venous occlusion significant vision loss retinal disease cause current visual impairment would likely cause visual impairment time period study . Currently use concomitant medication strong inhibitor inducer CYP3A4 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>MAPK</keyword>
	<keyword>RAS</keyword>
	<keyword>BRAF</keyword>
</DOC>